Global Hormonal Therapy for Cancer Market Growth (Status and Outlook) 2026-2032
The global Hormonal Therapy for Cancer market size is predicted to grow from US$ 17650 million in 2025 to US$ 42750 million in 2032; it is expected to grow at a CAGR of 13.7% from 2026 to 2032.
Hormonal therapy for cancer is a class of treatments that modulate endocrine signaling to inhibit or block the growth of hormone-dependent tumors. Approaches include suppressing hormone synthesis, blocking hormone receptors, and using receptor modulators; these are widely applied in estrogen- or androgen-sensitive cancers such as breast and prostate cancer. Hormonal therapy may be used as adjuvant treatment in early-stage disease to reduce recurrence risk, and as long-term maintenance or symptom-control therapy in advanced or metastatic settings. Recent advances in molecular subtyping, companion diagnostics, and combination regimens have elevated the role of hormonal therapies within precision oncology, prompting pharmaceutical firms to invest more in drug optimization, label expansion, and co-development with other targeted or immune agents—creating fresh commercialization and value-chain integration opportunities.
Hormonal therapy for cancer is at an inflection point, shifting from traditional mono-therapy maintenance to precision-guided and combination strategies. Annual reports from major pharmaceutical firms emphasize that label expansion, companion diagnostics, and combinations with novel small molecules or biologics can convert long-standing hormonal platforms into higher-value clinical solutions. Regulators’ increasing focus on biomarker-driven indications and combination regimens—including expedited review pathways in some jurisdictions—provides policy support for faster clinical adoption. Meanwhile, capital markets and M&A activity favor platform companies with expandable treatment lines and robust clinical evidence, concentrating resources on projects with combination potential and diagnostic capabilities, thereby accelerating innovation and commercialization.
Opportunities come with material uncertainty. Combination regimens and indication expansions require lengthy clinical validation and complex regulatory pathways, increasing upfront investment and time to market. Annual reports and regulatory notices highlight risks from patent expiries, generic competition, and reimbursement policy shifts that can disrupt established revenue models. Furthermore, commercialization of companion diagnostics demands cross-sector collaboration (pharma, diagnostics, clinical services); delays or mismatches in any link can slow overall launch. Thus, while pursuing efficacy and differentiation, firms must concurrently manage R&D, compliance, and supply-chain pressures.
Downstream demand is evolving from outcome-centric to continuity-and-connectivity-centric. Clinicians now evaluate hormonal regimens not only for efficacy and safety, but also for long-term management convenience and integration with imaging and molecular testing. Pharma partnerships with clinical research organizations and diagnostics firms on companion assays and real-world evidence generation are intensifying, shifting commercial models from pure product supply toward service-oriented platforms. For marketing and investor audiences, companies that can demonstrate an end-to-end value chain—from drug to diagnostic to follow-up—are more likely to capture procurement and capital attention.
The upstream ecosystem for hormonal therapies and related combination products includes active pharmaceutical ingredients (APIs), advanced formulation excipients and delivery technologies, and molecular reagents for companion diagnostics. Annual reports indicate that global supply availability, consistent quality, and regulatory compliance of key APIs and diagnostic reagents critically impact the ability to scale production and enter new markets rapidly. In the face of geopolitical and trade policy volatility, firms that achieve regionalized sourcing or upstream self-sufficiency will realize durable advantages in cost, delivery reliability, and compliance—foundations that underpin downstream commercialization.
This Insight Report provides a comprehensive analysis of the global Hormonal Therapy for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Hormonal Therapy for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hormonal Therapy for Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hormonal Therapy for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hormonal Therapy for Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Hormonal Therapy for Cancer market by product type, application, key players and key regions and countries.
Hormonal therapy for cancer is a class of treatments that modulate endocrine signaling to inhibit or block the growth of hormone-dependent tumors. Approaches include suppressing hormone synthesis, blocking hormone receptors, and using receptor modulators; these are widely applied in estrogen- or androgen-sensitive cancers such as breast and prostate cancer. Hormonal therapy may be used as adjuvant treatment in early-stage disease to reduce recurrence risk, and as long-term maintenance or symptom-control therapy in advanced or metastatic settings. Recent advances in molecular subtyping, companion diagnostics, and combination regimens have elevated the role of hormonal therapies within precision oncology, prompting pharmaceutical firms to invest more in drug optimization, label expansion, and co-development with other targeted or immune agents—creating fresh commercialization and value-chain integration opportunities.
Hormonal therapy for cancer is at an inflection point, shifting from traditional mono-therapy maintenance to precision-guided and combination strategies. Annual reports from major pharmaceutical firms emphasize that label expansion, companion diagnostics, and combinations with novel small molecules or biologics can convert long-standing hormonal platforms into higher-value clinical solutions. Regulators’ increasing focus on biomarker-driven indications and combination regimens—including expedited review pathways in some jurisdictions—provides policy support for faster clinical adoption. Meanwhile, capital markets and M&A activity favor platform companies with expandable treatment lines and robust clinical evidence, concentrating resources on projects with combination potential and diagnostic capabilities, thereby accelerating innovation and commercialization.
Opportunities come with material uncertainty. Combination regimens and indication expansions require lengthy clinical validation and complex regulatory pathways, increasing upfront investment and time to market. Annual reports and regulatory notices highlight risks from patent expiries, generic competition, and reimbursement policy shifts that can disrupt established revenue models. Furthermore, commercialization of companion diagnostics demands cross-sector collaboration (pharma, diagnostics, clinical services); delays or mismatches in any link can slow overall launch. Thus, while pursuing efficacy and differentiation, firms must concurrently manage R&D, compliance, and supply-chain pressures.
Downstream demand is evolving from outcome-centric to continuity-and-connectivity-centric. Clinicians now evaluate hormonal regimens not only for efficacy and safety, but also for long-term management convenience and integration with imaging and molecular testing. Pharma partnerships with clinical research organizations and diagnostics firms on companion assays and real-world evidence generation are intensifying, shifting commercial models from pure product supply toward service-oriented platforms. For marketing and investor audiences, companies that can demonstrate an end-to-end value chain—from drug to diagnostic to follow-up—are more likely to capture procurement and capital attention.
The upstream ecosystem for hormonal therapies and related combination products includes active pharmaceutical ingredients (APIs), advanced formulation excipients and delivery technologies, and molecular reagents for companion diagnostics. Annual reports indicate that global supply availability, consistent quality, and regulatory compliance of key APIs and diagnostic reagents critically impact the ability to scale production and enter new markets rapidly. In the face of geopolitical and trade policy volatility, firms that achieve regionalized sourcing or upstream self-sufficiency will realize durable advantages in cost, delivery reliability, and compliance—foundations that underpin downstream commercialization.
Report Scope
LPI (LP Information)' newest research report, the “Hormonal Therapy for Cancer Industry Forecast” looks at past sales and reviews total world Hormonal Therapy for Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Hormonal Therapy for Cancer sales for 2026 through 2032. With Hormonal Therapy for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hormonal Therapy for Cancer industry.This Insight Report provides a comprehensive analysis of the global Hormonal Therapy for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Hormonal Therapy for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hormonal Therapy for Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hormonal Therapy for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hormonal Therapy for Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Hormonal Therapy for Cancer market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- Tablet
- Capsule
- Injection
- Others
Segmentation by Application:
- Hospital
- Retail Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GlaxoSmithKline
- Jiangsu Haosen
- Sun Pharmaceutical
- Hengrui Medical
- Dr Reddy's Laboratories
- Astellas Pharma
- Sumitomo Pharma
- Johnson & Johnson
- Bayer AG
- Pfizer
- AstraZeneca
- Novartis
- Ferring Pharmaceuticals
- Myovant Sciences
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Hormonal Therapy for Cancer Market Size (2021-2032)
2.1.2 Hormonal Therapy for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Hormonal Therapy for Cancer by Country/Region (2021, 2025 & 2032)
2.2 Hormonal Therapy for Cancer Segment by Type
2.2.1 Tablet
2.2.2 Capsule
2.2.3 Injection
2.2.4 Others
2.2.5 Hormonal Therapy for Cancer Market Size by Type
2.2.5.1 Hormonal Therapy for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
2.3 Hormonal Therapy for Cancer Segment by Application
2.3.1 Hospital
2.3.2 Retail Pharmacy
2.3.3 Other
2.3.4 Hormonal Therapy for Cancer Market Size by Application
2.3.4.1 Hormonal Therapy for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
3 HORMONAL THERAPY FOR CANCER MARKET SIZE BY PLAYER
3.1 Hormonal Therapy for Cancer Market Size Market Share by Player
3.1.1 Global Hormonal Therapy for Cancer Revenue by Player (2021-2026)
3.1.2 Global Hormonal Therapy for Cancer Revenue Market Share by Player (2021-2026)
3.2 Global Hormonal Therapy for Cancer Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 HORMONAL THERAPY FOR CANCER BY REGION
4.1 Hormonal Therapy for Cancer Market Size by Region (2021-2026)
4.2 Global Hormonal Therapy for Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas Hormonal Therapy for Cancer Market Size Growth (2021-2026)
4.4 APAC Hormonal Therapy for Cancer Market Size Growth (2021-2026)
4.5 Europe Hormonal Therapy for Cancer Market Size Growth (2021-2026)
4.6 Middle East & Africa Hormonal Therapy for Cancer Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Hormonal Therapy for Cancer Market Size by Country (2021-2026)
5.2 Americas Hormonal Therapy for Cancer Market Size by Type (2021-2026)
5.3 Americas Hormonal Therapy for Cancer Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hormonal Therapy for Cancer Market Size by Region (2021-2026)
6.2 APAC Hormonal Therapy for Cancer Market Size by Type (2021-2026)
6.3 APAC Hormonal Therapy for Cancer Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Hormonal Therapy for Cancer Market Size by Country (2021-2026)
7.2 Europe Hormonal Therapy for Cancer Market Size by Type (2021-2026)
7.3 Europe Hormonal Therapy for Cancer Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Hormonal Therapy for Cancer by Region (2021-2026)
8.2 Middle East & Africa Hormonal Therapy for Cancer Market Size by Type (2021-2026)
8.3 Middle East & Africa Hormonal Therapy for Cancer Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL HORMONAL THERAPY FOR CANCER MARKET FORECAST
10.1 Global Hormonal Therapy for Cancer Forecast by Region (2027-2032)
10.1.1 Global Hormonal Therapy for Cancer Forecast by Region (2027-2032)
10.1.2 Americas Hormonal Therapy for Cancer Forecast
10.1.3 APAC Hormonal Therapy for Cancer Forecast
10.1.4 Europe Hormonal Therapy for Cancer Forecast
10.1.5 Middle East & Africa Hormonal Therapy for Cancer Forecast
10.2 Americas Hormonal Therapy for Cancer Forecast by Country (2027-2032)
10.2.1 United States Market Hormonal Therapy for Cancer Forecast
10.2.2 Canada Market Hormonal Therapy for Cancer Forecast
10.2.3 Mexico Market Hormonal Therapy for Cancer Forecast
10.2.4 Brazil Market Hormonal Therapy for Cancer Forecast
10.3 APAC Hormonal Therapy for Cancer Forecast by Region (2027-2032)
10.3.1 China Hormonal Therapy for Cancer Market Forecast
10.3.2 Japan Market Hormonal Therapy for Cancer Forecast
10.3.3 Korea Market Hormonal Therapy for Cancer Forecast
10.3.4 Southeast Asia Market Hormonal Therapy for Cancer Forecast
10.3.5 India Market Hormonal Therapy for Cancer Forecast
10.3.6 Australia Market Hormonal Therapy for Cancer Forecast
10.4 Europe Hormonal Therapy for Cancer Forecast by Country (2027-2032)
10.4.1 Germany Market Hormonal Therapy for Cancer Forecast
10.4.2 France Market Hormonal Therapy for Cancer Forecast
10.4.3 UK Market Hormonal Therapy for Cancer Forecast
10.4.4 Italy Market Hormonal Therapy for Cancer Forecast
10.4.5 Russia Market Hormonal Therapy for Cancer Forecast
10.5 Middle East & Africa Hormonal Therapy for Cancer Forecast by Region (2027-2032)
10.5.1 Egypt Market Hormonal Therapy for Cancer Forecast
10.5.2 South Africa Market Hormonal Therapy for Cancer Forecast
10.5.3 Israel Market Hormonal Therapy for Cancer Forecast
10.5.4 Turkey Market Hormonal Therapy for Cancer Forecast
10.6 Global Hormonal Therapy for Cancer Forecast by Type (2027-2032)
10.7 Global Hormonal Therapy for Cancer Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Hormonal Therapy for Cancer Forecast
11 KEY PLAYERS ANALYSIS
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Information
11.1.2 GlaxoSmithKline Hormonal Therapy for Cancer Product Offered
11.1.3 GlaxoSmithKline Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 GlaxoSmithKline Main Business Overview
11.1.5 GlaxoSmithKline Latest Developments
11.2 Jiangsu Haosen
11.2.1 Jiangsu Haosen Company Information
11.2.2 Jiangsu Haosen Hormonal Therapy for Cancer Product Offered
11.2.3 Jiangsu Haosen Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Jiangsu Haosen Main Business Overview
11.2.5 Jiangsu Haosen Latest Developments
11.3 Sun Pharmaceutical
11.3.1 Sun Pharmaceutical Company Information
11.3.2 Sun Pharmaceutical Hormonal Therapy for Cancer Product Offered
11.3.3 Sun Pharmaceutical Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Sun Pharmaceutical Main Business Overview
11.3.5 Sun Pharmaceutical Latest Developments
11.4 Hengrui Medical
11.4.1 Hengrui Medical Company Information
11.4.2 Hengrui Medical Hormonal Therapy for Cancer Product Offered
11.4.3 Hengrui Medical Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Hengrui Medical Main Business Overview
11.4.5 Hengrui Medical Latest Developments
11.5 Dr Reddy's Laboratories
11.5.1 Dr Reddy's Laboratories Company Information
11.5.2 Dr Reddy's Laboratories Hormonal Therapy for Cancer Product Offered
11.5.3 Dr Reddy's Laboratories Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Dr Reddy's Laboratories Main Business Overview
11.5.5 Dr Reddy's Laboratories Latest Developments
11.6 Astellas Pharma
11.6.1 Astellas Pharma Company Information
11.6.2 Astellas Pharma Hormonal Therapy for Cancer Product Offered
11.6.3 Astellas Pharma Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Astellas Pharma Main Business Overview
11.6.5 Astellas Pharma Latest Developments
11.7 Sumitomo Pharma
11.7.1 Sumitomo Pharma Company Information
11.7.2 Sumitomo Pharma Hormonal Therapy for Cancer Product Offered
11.7.3 Sumitomo Pharma Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Sumitomo Pharma Main Business Overview
11.7.5 Sumitomo Pharma Latest Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Information
11.8.2 Johnson & Johnson Hormonal Therapy for Cancer Product Offered
11.8.3 Johnson & Johnson Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Johnson & Johnson Main Business Overview
11.8.5 Johnson & Johnson Latest Developments
11.9 Bayer AG
11.9.1 Bayer AG Company Information
11.9.2 Bayer AG Hormonal Therapy for Cancer Product Offered
11.9.3 Bayer AG Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Bayer AG Main Business Overview
11.9.5 Bayer AG Latest Developments
11.10 Pfizer
11.10.1 Pfizer Company Information
11.10.2 Pfizer Hormonal Therapy for Cancer Product Offered
11.10.3 Pfizer Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Pfizer Main Business Overview
11.10.5 Pfizer Latest Developments
11.11 AstraZeneca
11.11.1 AstraZeneca Company Information
11.11.2 AstraZeneca Hormonal Therapy for Cancer Product Offered
11.11.3 AstraZeneca Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 AstraZeneca Main Business Overview
11.11.5 AstraZeneca Latest Developments
11.12 Novartis
11.12.1 Novartis Company Information
11.12.2 Novartis Hormonal Therapy for Cancer Product Offered
11.12.3 Novartis Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Novartis Main Business Overview
11.12.5 Novartis Latest Developments
11.13 Ferring Pharmaceuticals
11.13.1 Ferring Pharmaceuticals Company Information
11.13.2 Ferring Pharmaceuticals Hormonal Therapy for Cancer Product Offered
11.13.3 Ferring Pharmaceuticals Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Ferring Pharmaceuticals Main Business Overview
11.13.5 Ferring Pharmaceuticals Latest Developments
11.14 Myovant Sciences
11.14.1 Myovant Sciences Company Information
11.14.2 Myovant Sciences Hormonal Therapy for Cancer Product Offered
11.14.3 Myovant Sciences Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Myovant Sciences Main Business Overview
11.14.5 Myovant Sciences Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Hormonal Therapy for Cancer Market Size (2021-2032)
2.1.2 Hormonal Therapy for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Hormonal Therapy for Cancer by Country/Region (2021, 2025 & 2032)
2.2 Hormonal Therapy for Cancer Segment by Type
2.2.1 Tablet
2.2.2 Capsule
2.2.3 Injection
2.2.4 Others
2.2.5 Hormonal Therapy for Cancer Market Size by Type
2.2.5.1 Hormonal Therapy for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
2.3 Hormonal Therapy for Cancer Segment by Application
2.3.1 Hospital
2.3.2 Retail Pharmacy
2.3.3 Other
2.3.4 Hormonal Therapy for Cancer Market Size by Application
2.3.4.1 Hormonal Therapy for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
3 HORMONAL THERAPY FOR CANCER MARKET SIZE BY PLAYER
3.1 Hormonal Therapy for Cancer Market Size Market Share by Player
3.1.1 Global Hormonal Therapy for Cancer Revenue by Player (2021-2026)
3.1.2 Global Hormonal Therapy for Cancer Revenue Market Share by Player (2021-2026)
3.2 Global Hormonal Therapy for Cancer Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 HORMONAL THERAPY FOR CANCER BY REGION
4.1 Hormonal Therapy for Cancer Market Size by Region (2021-2026)
4.2 Global Hormonal Therapy for Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas Hormonal Therapy for Cancer Market Size Growth (2021-2026)
4.4 APAC Hormonal Therapy for Cancer Market Size Growth (2021-2026)
4.5 Europe Hormonal Therapy for Cancer Market Size Growth (2021-2026)
4.6 Middle East & Africa Hormonal Therapy for Cancer Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Hormonal Therapy for Cancer Market Size by Country (2021-2026)
5.2 Americas Hormonal Therapy for Cancer Market Size by Type (2021-2026)
5.3 Americas Hormonal Therapy for Cancer Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hormonal Therapy for Cancer Market Size by Region (2021-2026)
6.2 APAC Hormonal Therapy for Cancer Market Size by Type (2021-2026)
6.3 APAC Hormonal Therapy for Cancer Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Hormonal Therapy for Cancer Market Size by Country (2021-2026)
7.2 Europe Hormonal Therapy for Cancer Market Size by Type (2021-2026)
7.3 Europe Hormonal Therapy for Cancer Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Hormonal Therapy for Cancer by Region (2021-2026)
8.2 Middle East & Africa Hormonal Therapy for Cancer Market Size by Type (2021-2026)
8.3 Middle East & Africa Hormonal Therapy for Cancer Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL HORMONAL THERAPY FOR CANCER MARKET FORECAST
10.1 Global Hormonal Therapy for Cancer Forecast by Region (2027-2032)
10.1.1 Global Hormonal Therapy for Cancer Forecast by Region (2027-2032)
10.1.2 Americas Hormonal Therapy for Cancer Forecast
10.1.3 APAC Hormonal Therapy for Cancer Forecast
10.1.4 Europe Hormonal Therapy for Cancer Forecast
10.1.5 Middle East & Africa Hormonal Therapy for Cancer Forecast
10.2 Americas Hormonal Therapy for Cancer Forecast by Country (2027-2032)
10.2.1 United States Market Hormonal Therapy for Cancer Forecast
10.2.2 Canada Market Hormonal Therapy for Cancer Forecast
10.2.3 Mexico Market Hormonal Therapy for Cancer Forecast
10.2.4 Brazil Market Hormonal Therapy for Cancer Forecast
10.3 APAC Hormonal Therapy for Cancer Forecast by Region (2027-2032)
10.3.1 China Hormonal Therapy for Cancer Market Forecast
10.3.2 Japan Market Hormonal Therapy for Cancer Forecast
10.3.3 Korea Market Hormonal Therapy for Cancer Forecast
10.3.4 Southeast Asia Market Hormonal Therapy for Cancer Forecast
10.3.5 India Market Hormonal Therapy for Cancer Forecast
10.3.6 Australia Market Hormonal Therapy for Cancer Forecast
10.4 Europe Hormonal Therapy for Cancer Forecast by Country (2027-2032)
10.4.1 Germany Market Hormonal Therapy for Cancer Forecast
10.4.2 France Market Hormonal Therapy for Cancer Forecast
10.4.3 UK Market Hormonal Therapy for Cancer Forecast
10.4.4 Italy Market Hormonal Therapy for Cancer Forecast
10.4.5 Russia Market Hormonal Therapy for Cancer Forecast
10.5 Middle East & Africa Hormonal Therapy for Cancer Forecast by Region (2027-2032)
10.5.1 Egypt Market Hormonal Therapy for Cancer Forecast
10.5.2 South Africa Market Hormonal Therapy for Cancer Forecast
10.5.3 Israel Market Hormonal Therapy for Cancer Forecast
10.5.4 Turkey Market Hormonal Therapy for Cancer Forecast
10.6 Global Hormonal Therapy for Cancer Forecast by Type (2027-2032)
10.7 Global Hormonal Therapy for Cancer Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Hormonal Therapy for Cancer Forecast
11 KEY PLAYERS ANALYSIS
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Information
11.1.2 GlaxoSmithKline Hormonal Therapy for Cancer Product Offered
11.1.3 GlaxoSmithKline Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 GlaxoSmithKline Main Business Overview
11.1.5 GlaxoSmithKline Latest Developments
11.2 Jiangsu Haosen
11.2.1 Jiangsu Haosen Company Information
11.2.2 Jiangsu Haosen Hormonal Therapy for Cancer Product Offered
11.2.3 Jiangsu Haosen Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Jiangsu Haosen Main Business Overview
11.2.5 Jiangsu Haosen Latest Developments
11.3 Sun Pharmaceutical
11.3.1 Sun Pharmaceutical Company Information
11.3.2 Sun Pharmaceutical Hormonal Therapy for Cancer Product Offered
11.3.3 Sun Pharmaceutical Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Sun Pharmaceutical Main Business Overview
11.3.5 Sun Pharmaceutical Latest Developments
11.4 Hengrui Medical
11.4.1 Hengrui Medical Company Information
11.4.2 Hengrui Medical Hormonal Therapy for Cancer Product Offered
11.4.3 Hengrui Medical Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Hengrui Medical Main Business Overview
11.4.5 Hengrui Medical Latest Developments
11.5 Dr Reddy's Laboratories
11.5.1 Dr Reddy's Laboratories Company Information
11.5.2 Dr Reddy's Laboratories Hormonal Therapy for Cancer Product Offered
11.5.3 Dr Reddy's Laboratories Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Dr Reddy's Laboratories Main Business Overview
11.5.5 Dr Reddy's Laboratories Latest Developments
11.6 Astellas Pharma
11.6.1 Astellas Pharma Company Information
11.6.2 Astellas Pharma Hormonal Therapy for Cancer Product Offered
11.6.3 Astellas Pharma Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Astellas Pharma Main Business Overview
11.6.5 Astellas Pharma Latest Developments
11.7 Sumitomo Pharma
11.7.1 Sumitomo Pharma Company Information
11.7.2 Sumitomo Pharma Hormonal Therapy for Cancer Product Offered
11.7.3 Sumitomo Pharma Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Sumitomo Pharma Main Business Overview
11.7.5 Sumitomo Pharma Latest Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Information
11.8.2 Johnson & Johnson Hormonal Therapy for Cancer Product Offered
11.8.3 Johnson & Johnson Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Johnson & Johnson Main Business Overview
11.8.5 Johnson & Johnson Latest Developments
11.9 Bayer AG
11.9.1 Bayer AG Company Information
11.9.2 Bayer AG Hormonal Therapy for Cancer Product Offered
11.9.3 Bayer AG Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Bayer AG Main Business Overview
11.9.5 Bayer AG Latest Developments
11.10 Pfizer
11.10.1 Pfizer Company Information
11.10.2 Pfizer Hormonal Therapy for Cancer Product Offered
11.10.3 Pfizer Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Pfizer Main Business Overview
11.10.5 Pfizer Latest Developments
11.11 AstraZeneca
11.11.1 AstraZeneca Company Information
11.11.2 AstraZeneca Hormonal Therapy for Cancer Product Offered
11.11.3 AstraZeneca Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 AstraZeneca Main Business Overview
11.11.5 AstraZeneca Latest Developments
11.12 Novartis
11.12.1 Novartis Company Information
11.12.2 Novartis Hormonal Therapy for Cancer Product Offered
11.12.3 Novartis Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Novartis Main Business Overview
11.12.5 Novartis Latest Developments
11.13 Ferring Pharmaceuticals
11.13.1 Ferring Pharmaceuticals Company Information
11.13.2 Ferring Pharmaceuticals Hormonal Therapy for Cancer Product Offered
11.13.3 Ferring Pharmaceuticals Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Ferring Pharmaceuticals Main Business Overview
11.13.5 Ferring Pharmaceuticals Latest Developments
11.14 Myovant Sciences
11.14.1 Myovant Sciences Company Information
11.14.2 Myovant Sciences Hormonal Therapy for Cancer Product Offered
11.14.3 Myovant Sciences Hormonal Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Myovant Sciences Main Business Overview
11.14.5 Myovant Sciences Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Hormonal Therapy for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Hormonal Therapy for Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Tablet
Table 4. Major Players of Capsule
Table 5. Major Players of Injection
Table 6. Major Players of Others
Table 7. Hormonal Therapy for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Table 10. Hormonal Therapy for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Table 13. Global Hormonal Therapy for Cancer Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Hormonal Therapy for Cancer Revenue Market Share by Player (2021-2026)
Table 15. Hormonal Therapy for Cancer Key Players Head office and Products Offered
Table 16. Hormonal Therapy for Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Hormonal Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Hormonal Therapy for Cancer Market Size Market Share by Region (2021-2026)
Table 21. Global Hormonal Therapy for Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Hormonal Therapy for Cancer Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Hormonal Therapy for Cancer Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Hormonal Therapy for Cancer Market Size Market Share by Country (2021-2026)
Table 25. Americas Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Table 27. Americas Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Table 29. APAC Hormonal Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Hormonal Therapy for Cancer Market Size Market Share by Region (2021-2026)
Table 31. APAC Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Hormonal Therapy for Cancer Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Hormonal Therapy for Cancer Market Size Market Share by Country (2021-2026)
Table 35. Europe Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Hormonal Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Hormonal Therapy for Cancer
Table 41. Key Market Challenges & Risks of Hormonal Therapy for Cancer
Table 42. Key Industry Trends of Hormonal Therapy for Cancer
Table 43. Global Hormonal Therapy for Cancer Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Hormonal Therapy for Cancer Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Hormonal Therapy for Cancer Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Hormonal Therapy for Cancer Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. GlaxoSmithKline Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 48. GlaxoSmithKline Hormonal Therapy for Cancer Product Offered
Table 49. GlaxoSmithKline Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. GlaxoSmithKline Main Business
Table 51. GlaxoSmithKline Latest Developments
Table 52. Jiangsu Haosen Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 53. Jiangsu Haosen Hormonal Therapy for Cancer Product Offered
Table 54. Jiangsu Haosen Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. Jiangsu Haosen Main Business
Table 56. Jiangsu Haosen Latest Developments
Table 57. Sun Pharmaceutical Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 58. Sun Pharmaceutical Hormonal Therapy for Cancer Product Offered
Table 59. Sun Pharmaceutical Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Sun Pharmaceutical Main Business
Table 61. Sun Pharmaceutical Latest Developments
Table 62. Hengrui Medical Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 63. Hengrui Medical Hormonal Therapy for Cancer Product Offered
Table 64. Hengrui Medical Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Hengrui Medical Main Business
Table 66. Hengrui Medical Latest Developments
Table 67. Dr Reddy's Laboratories Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 68. Dr Reddy's Laboratories Hormonal Therapy for Cancer Product Offered
Table 69. Dr Reddy's Laboratories Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Dr Reddy's Laboratories Main Business
Table 71. Dr Reddy's Laboratories Latest Developments
Table 72. Astellas Pharma Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 73. Astellas Pharma Hormonal Therapy for Cancer Product Offered
Table 74. Astellas Pharma Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Astellas Pharma Main Business
Table 76. Astellas Pharma Latest Developments
Table 77. Sumitomo Pharma Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 78. Sumitomo Pharma Hormonal Therapy for Cancer Product Offered
Table 79. Sumitomo Pharma Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Sumitomo Pharma Main Business
Table 81. Sumitomo Pharma Latest Developments
Table 82. Johnson & Johnson Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 83. Johnson & Johnson Hormonal Therapy for Cancer Product Offered
Table 84. Johnson & Johnson Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Johnson & Johnson Main Business
Table 86. Johnson & Johnson Latest Developments
Table 87. Bayer AG Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 88. Bayer AG Hormonal Therapy for Cancer Product Offered
Table 89. Bayer AG Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Bayer AG Main Business
Table 91. Bayer AG Latest Developments
Table 92. Pfizer Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 93. Pfizer Hormonal Therapy for Cancer Product Offered
Table 94. Pfizer Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Pfizer Main Business
Table 96. Pfizer Latest Developments
Table 97. AstraZeneca Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 98. AstraZeneca Hormonal Therapy for Cancer Product Offered
Table 99. AstraZeneca Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. AstraZeneca Main Business
Table 101. AstraZeneca Latest Developments
Table 102. Novartis Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 103. Novartis Hormonal Therapy for Cancer Product Offered
Table 104. Novartis Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Novartis Main Business
Table 106. Novartis Latest Developments
Table 107. Ferring Pharmaceuticals Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 108. Ferring Pharmaceuticals Hormonal Therapy for Cancer Product Offered
Table 109. Ferring Pharmaceuticals Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Ferring Pharmaceuticals Main Business
Table 111. Ferring Pharmaceuticals Latest Developments
Table 112. Myovant Sciences Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 113. Myovant Sciences Hormonal Therapy for Cancer Product Offered
Table 114. Myovant Sciences Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. Myovant Sciences Main Business
Table 116. Myovant Sciences Latest Developments
Table 1. Hormonal Therapy for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Hormonal Therapy for Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Tablet
Table 4. Major Players of Capsule
Table 5. Major Players of Injection
Table 6. Major Players of Others
Table 7. Hormonal Therapy for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Table 10. Hormonal Therapy for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Table 13. Global Hormonal Therapy for Cancer Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Hormonal Therapy for Cancer Revenue Market Share by Player (2021-2026)
Table 15. Hormonal Therapy for Cancer Key Players Head office and Products Offered
Table 16. Hormonal Therapy for Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Hormonal Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Hormonal Therapy for Cancer Market Size Market Share by Region (2021-2026)
Table 21. Global Hormonal Therapy for Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Hormonal Therapy for Cancer Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Hormonal Therapy for Cancer Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Hormonal Therapy for Cancer Market Size Market Share by Country (2021-2026)
Table 25. Americas Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Table 27. Americas Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Table 29. APAC Hormonal Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Hormonal Therapy for Cancer Market Size Market Share by Region (2021-2026)
Table 31. APAC Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Hormonal Therapy for Cancer Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Hormonal Therapy for Cancer Market Size Market Share by Country (2021-2026)
Table 35. Europe Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Hormonal Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Hormonal Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Hormonal Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Hormonal Therapy for Cancer
Table 41. Key Market Challenges & Risks of Hormonal Therapy for Cancer
Table 42. Key Industry Trends of Hormonal Therapy for Cancer
Table 43. Global Hormonal Therapy for Cancer Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Hormonal Therapy for Cancer Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Hormonal Therapy for Cancer Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Hormonal Therapy for Cancer Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. GlaxoSmithKline Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 48. GlaxoSmithKline Hormonal Therapy for Cancer Product Offered
Table 49. GlaxoSmithKline Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. GlaxoSmithKline Main Business
Table 51. GlaxoSmithKline Latest Developments
Table 52. Jiangsu Haosen Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 53. Jiangsu Haosen Hormonal Therapy for Cancer Product Offered
Table 54. Jiangsu Haosen Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. Jiangsu Haosen Main Business
Table 56. Jiangsu Haosen Latest Developments
Table 57. Sun Pharmaceutical Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 58. Sun Pharmaceutical Hormonal Therapy for Cancer Product Offered
Table 59. Sun Pharmaceutical Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Sun Pharmaceutical Main Business
Table 61. Sun Pharmaceutical Latest Developments
Table 62. Hengrui Medical Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 63. Hengrui Medical Hormonal Therapy for Cancer Product Offered
Table 64. Hengrui Medical Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Hengrui Medical Main Business
Table 66. Hengrui Medical Latest Developments
Table 67. Dr Reddy's Laboratories Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 68. Dr Reddy's Laboratories Hormonal Therapy for Cancer Product Offered
Table 69. Dr Reddy's Laboratories Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Dr Reddy's Laboratories Main Business
Table 71. Dr Reddy's Laboratories Latest Developments
Table 72. Astellas Pharma Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 73. Astellas Pharma Hormonal Therapy for Cancer Product Offered
Table 74. Astellas Pharma Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Astellas Pharma Main Business
Table 76. Astellas Pharma Latest Developments
Table 77. Sumitomo Pharma Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 78. Sumitomo Pharma Hormonal Therapy for Cancer Product Offered
Table 79. Sumitomo Pharma Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Sumitomo Pharma Main Business
Table 81. Sumitomo Pharma Latest Developments
Table 82. Johnson & Johnson Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 83. Johnson & Johnson Hormonal Therapy for Cancer Product Offered
Table 84. Johnson & Johnson Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Johnson & Johnson Main Business
Table 86. Johnson & Johnson Latest Developments
Table 87. Bayer AG Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 88. Bayer AG Hormonal Therapy for Cancer Product Offered
Table 89. Bayer AG Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Bayer AG Main Business
Table 91. Bayer AG Latest Developments
Table 92. Pfizer Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 93. Pfizer Hormonal Therapy for Cancer Product Offered
Table 94. Pfizer Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Pfizer Main Business
Table 96. Pfizer Latest Developments
Table 97. AstraZeneca Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 98. AstraZeneca Hormonal Therapy for Cancer Product Offered
Table 99. AstraZeneca Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. AstraZeneca Main Business
Table 101. AstraZeneca Latest Developments
Table 102. Novartis Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 103. Novartis Hormonal Therapy for Cancer Product Offered
Table 104. Novartis Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Novartis Main Business
Table 106. Novartis Latest Developments
Table 107. Ferring Pharmaceuticals Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 108. Ferring Pharmaceuticals Hormonal Therapy for Cancer Product Offered
Table 109. Ferring Pharmaceuticals Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Ferring Pharmaceuticals Main Business
Table 111. Ferring Pharmaceuticals Latest Developments
Table 112. Myovant Sciences Details, Company Type, Hormonal Therapy for Cancer Area Served and Its Competitors
Table 113. Myovant Sciences Hormonal Therapy for Cancer Product Offered
Table 114. Myovant Sciences Hormonal Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. Myovant Sciences Main Business
Table 116. Myovant Sciences Latest Developments
LIST OF FIGURES
Figure 1. Hormonal Therapy for Cancer Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Hormonal Therapy for Cancer Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Hormonal Therapy for Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Hormonal Therapy for Cancer Sales Market Share by Country/Region (2025)
Figure 8. Hormonal Therapy for Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Hormonal Therapy for Cancer Market Size Market Share by Type in 2025
Figure 10. Hormonal Therapy for Cancer in Hospital
Figure 11. Global Hormonal Therapy for Cancer Market: Hospital (2021-2026) & ($ millions)
Figure 12. Hormonal Therapy for Cancer in Retail Pharmacy
Figure 13. Global Hormonal Therapy for Cancer Market: Retail Pharmacy (2021-2026) & ($ millions)
Figure 14. Hormonal Therapy for Cancer in Other
Figure 15. Global Hormonal Therapy for Cancer Market: Other (2021-2026) & ($ millions)
Figure 16. Global Hormonal Therapy for Cancer Market Size Market Share by Application in 2025
Figure 17. Global Hormonal Therapy for Cancer Revenue Market Share by Player in 2025
Figure 18. Global Hormonal Therapy for Cancer Market Size Market Share by Region (2021-2026)
Figure 19. Americas Hormonal Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 20. APAC Hormonal Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 21. Europe Hormonal Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Hormonal Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 23. Americas Hormonal Therapy for Cancer Value Market Share by Country in 2025
Figure 24. United States Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Hormonal Therapy for Cancer Market Size Market Share by Region in 2025
Figure 29. APAC Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 30. APAC Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 31. China Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 35. India Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Hormonal Therapy for Cancer Market Size Market Share by Country in 2025
Figure 38. Europe Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 39. Europe Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 40. Germany Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 41. France Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Hormonal Therapy for Cancer Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 54. APAC Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 55. Europe Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 57. United States Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 58. Canada Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 59. Mexico Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 60. Brazil Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 61. China Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 62. Japan Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 63. Korea Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 65. India Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 66. Australia Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 67. Germany Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 68. France Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 69. UK Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 70. Italy Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 71. Russia Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 72. Egypt Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 73. South Africa Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 74. Israel Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 75. Turkey Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 76. Global Hormonal Therapy for Cancer Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Hormonal Therapy for Cancer Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 1. Hormonal Therapy for Cancer Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Hormonal Therapy for Cancer Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Hormonal Therapy for Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Hormonal Therapy for Cancer Sales Market Share by Country/Region (2025)
Figure 8. Hormonal Therapy for Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Hormonal Therapy for Cancer Market Size Market Share by Type in 2025
Figure 10. Hormonal Therapy for Cancer in Hospital
Figure 11. Global Hormonal Therapy for Cancer Market: Hospital (2021-2026) & ($ millions)
Figure 12. Hormonal Therapy for Cancer in Retail Pharmacy
Figure 13. Global Hormonal Therapy for Cancer Market: Retail Pharmacy (2021-2026) & ($ millions)
Figure 14. Hormonal Therapy for Cancer in Other
Figure 15. Global Hormonal Therapy for Cancer Market: Other (2021-2026) & ($ millions)
Figure 16. Global Hormonal Therapy for Cancer Market Size Market Share by Application in 2025
Figure 17. Global Hormonal Therapy for Cancer Revenue Market Share by Player in 2025
Figure 18. Global Hormonal Therapy for Cancer Market Size Market Share by Region (2021-2026)
Figure 19. Americas Hormonal Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 20. APAC Hormonal Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 21. Europe Hormonal Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Hormonal Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 23. Americas Hormonal Therapy for Cancer Value Market Share by Country in 2025
Figure 24. United States Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Hormonal Therapy for Cancer Market Size Market Share by Region in 2025
Figure 29. APAC Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 30. APAC Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 31. China Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 35. India Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Hormonal Therapy for Cancer Market Size Market Share by Country in 2025
Figure 38. Europe Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 39. Europe Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 40. Germany Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 41. France Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Hormonal Therapy for Cancer Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Hormonal Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Hormonal Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Hormonal Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 54. APAC Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 55. Europe Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 57. United States Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 58. Canada Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 59. Mexico Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 60. Brazil Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 61. China Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 62. Japan Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 63. Korea Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 65. India Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 66. Australia Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 67. Germany Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 68. France Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 69. UK Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 70. Italy Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 71. Russia Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 72. Egypt Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 73. South Africa Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 74. Israel Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 75. Turkey Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 76. Global Hormonal Therapy for Cancer Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Hormonal Therapy for Cancer Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Hormonal Therapy for Cancer Market Size 2027-2032 ($ millions)
